Effects of Spironolactone on Matrix Metalloproteinases (MMPs) in Heart Failure
Sponsor
Tottori University Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT00663195
Collaborator
(none)
16
23
Study Details
Study Description
Brief Summary
The purpose of this study is to evaluate the effects of spironolactone on circulating MMP levels and insulin resistance in patients with chronic heart failure.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 4 |
Detailed Description
Myocardial fibrosis is observed in failing hearts. MMPs are considered markers of fibrosis. Recently, circulating MMPs can be measured and are elevated in patients with chronic heart failure (CHF). It has been reported that spironolactone improves myocardial fibrosis in CHF animal models. Therefore, the purpose of this study is to evaluate the effects of spironolactone on circulating MMP levels in patients with chronic heart failure.
Study Design
Study Type:
Interventional
Actual Enrollment
:
16 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
Effects of Spironolactone on Circulating MMPs in Patients With Chronic Heart Failure
Study Start Date
:
Jan 1, 2004
Actual Study Completion Date
:
Dec 1, 2005
Outcome Measures
Primary Outcome Measures
- MMP levels [16 weeks]
Eligibility Criteria
Criteria
Ages Eligible for Study:
N/A
and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
- chronic stable heart failure
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Tottori University Hospital
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00663195
Other Study ID Numbers:
- #344
First Posted:
Apr 22, 2008
Last Update Posted:
Apr 22, 2008
Last Verified:
Apr 1, 2008
Keywords provided by ,
,
Additional relevant MeSH terms: